Analysts Set Emergent BioSolutions Inc. (NYSE:EBS) Price Target at $47.60
Analysts Set Emergent BioSolutions Inc. (NYSE:EBS) Price Target at $47.60
Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) has been given a consensus recommendation of "Hold" by the seven ratings firms that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $47.60.
據MarketBeat.com報道，Emerent BioSolutions Inc.(紐約證券交易所代碼：EBS-GET Rating)已被覆蓋該公司的七家評級公司一致建議持有。四名分析師對該股的評級為持有，一名分析師對該公司的評級為買入。在過去一年追蹤該股的券商中，12個月目標價的平均水平為47.60美元。
Several analysts recently commented on the company. Cowen dropped their price target on Emergent BioSolutions from $30.00 to $29.00 and set a "market perform" rating for the company in a research report on Monday. Cowen dropped their target price on shares of Emergent BioSolutions from $30.00 to $29.00 and set a "market perform" rating for the company in a report on Monday.
幾位分析師最近對該公司發表了評論。考恩在週一的一份研究報告中將Emerent BioSolutions的目標價從30.00美元下調至29.00美元，併為該公司設定了“市場表現”評級。考恩在週一的一份報告中將Emerent BioSolutions的目標價從30.00美元下調至29.00美元，併為該公司設定了“市場表現”評級。
Institutional Investors Weigh In On Emergent BioSolutions
機構投資者參與新興生物解決方案
Several hedge funds and other institutional investors have recently bought and sold shares of EBS. State of Alaska Department of Revenue lifted its stake in shares of Emergent BioSolutions by 1.3% in the 2nd quarter. State of Alaska Department of Revenue now owns 33,825 shares of the biopharmaceutical company's stock valued at $1,049,000 after purchasing an additional 430 shares during the last quarter. Covestor Ltd lifted its position in Emergent BioSolutions by 43.8% in the first quarter. Covestor Ltd now owns 1,612 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 491 shares during the last quarter. Cutler Group LP boosted its stake in Emergent BioSolutions by 250.0% during the first quarter. Cutler Group LP now owns 700 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 500 shares during the period. Kendall Capital Management raised its stake in shares of Emergent BioSolutions by 4.7% in the 1st quarter. Kendall Capital Management now owns 11,585 shares of the biopharmaceutical company's stock valued at $476,000 after acquiring an additional 525 shares during the period. Finally, Centaurus Financial Inc. boosted its position in shares of Emergent BioSolutions by 14.4% during the 2nd quarter. Centaurus Financial Inc. now owns 4,342 shares of the biopharmaceutical company's stock worth $135,000 after purchasing an additional 546 shares during the period. 81.54% of the stock is currently owned by institutional investors and hedge funds.
幾家對衝基金和其他機構投資者最近買賣了EBS的股票。阿拉斯加州税務局在第二季度將其在Emerent BioSolutions的股份增加了1.3%。阿拉斯加州税務局在上個季度購買了430股後，現在擁有33,825股這家生物製藥公司的股票，價值1,049,000美元。Covestor Ltd在第一季度將其在Emerent BioSolutions的頭寸提高了43.8%。Covestor Ltd現在擁有這家生物製藥公司1,612股股票，價值66,000美元，此前在上個季度又購買了491股。卡特勒集團在第一季度增持了250.0%的艾默生生物解決方案股份。卡特勒集團現在持有700股這家生物製藥公司的股票，價值2.8萬美元，在此期間又購買了500股。肯德爾資本管理公司在第一季度增持了Emerent BioSolutions的股份4.7%。肯德爾資本管理公司現在擁有這家生物製藥公司11,585股股票，價值476,000美元，在此期間又購買了525股。最後，半人馬座金融公司在第二季度將其在Emerent BioSolutions的股票頭寸提高了14.4%。半人馬座金融公司現在持有這家生物製藥公司4,342股股票，價值135,000美元，在此期間又購買了546股。81.54%的股票目前由機構投資者和對衝基金持有。
Emergent BioSolutions Stock Down 0.7 %
Emerent BioSolutions股價下跌0.7%
Emergent BioSolutions (NYSE:EBS – Get Rating) last posted its quarterly earnings data on Monday, August 1st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($1.24). Emergent BioSolutions had a return on equity of 12.22% and a net margin of 6.02%. The firm had revenue of $242.70 million during the quarter, compared to analyst estimates of $268.77 million. During the same quarter in the previous year, the firm posted $0.33 earnings per share. The company's quarterly revenue was down 38.9% on a year-over-year basis. Equities analysts predict that Emergent BioSolutions will post -0.7 EPS for the current fiscal year.
Emerent BioSolutions(紐約證券交易所代碼：EBS-GET Rating)最近一次公佈季度收益數據是在8月1日星期一。這家生物製藥公司公佈了本季度每股收益(EPS)(0.86美元)，低於普遍預期的0.38美元(1.24美元)。Emerent BioSolutions的股本回報率為12.22%，淨利潤率為6.02%。該公司本季度營收為2.427億美元，而分析師預期為2.6877億美元。去年同期，該公司公佈的每股收益為0.33美元。該公司季度營收同比下降38.9%。股票分析師預測，Emerent BioSolutions本財年的每股收益將達到0.7%。
Emergent BioSolutions Company Profile
Emerent BioSolutions公司簡介
(Get Rating)
(獲取評級)
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.
Emerent BioSolutions Inc是一家生命科學公司，專注於提供準備和響應解決方案，以應對美國發生的意外、故意和自然發生的公共衞生威脅(PHTs)。該公司的產品涉及PHTs，包括化學、生物、輻射、核和爆炸物；新出現的傳染病；旅行健康；以及新出現的健康危機和急性/緊急護理。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Emergent BioSolutions (EBS)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- 免費獲取StockNews.com關於緊急生物解決方案(EBS)的研究報告
- 這家醫療設備製造商準備好繼續反彈了嗎？
- 第三季度財報公佈前最值得關注的五(5)只股票
- Take-Two Interactive是否已經退化為一招小馬？
- 具有有趣內幕活動的四隻廉價股票
- 健康飲料製造商Celsius能否超越其Monster競爭對手？
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Emerent BioSolutions Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對Emerent BioSolutions及相關公司的評級的每日摘要。